BTIG lowered the firm’s price target on DexCom (DXCM) to $85 from $109 and keeps a Buy rating on the shares. The company’s Q3 earnings beat was overshadowed by its below-consensus preliminary FY26 outlook, and sentiment remains “tough”, the analyst tells investors in a research note. DexCom’s profitability, product pipeline, market position and potential tailwinds still make the stock a high-quality name, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Dexcom Faces Challenges with G7 Device: Hold Rating Amidst Investor Caution
- DexCom price target lowered to $75 from $100 at Piper Sandler
- DexCom price target lowered to $75 from $85 at Citi
- DexCom price target lowered to $93 from $98 at Wells Fargo
- DexCom price target lowered to $99 from $106 at Canaccord